1 janv. 1998 - Trastuzumab
Description:
For the treatment of women with HER2-positive metastatic breast cancer, the Food and Drug Administration (FDA) recommends trastuzumab, a monoclonal antibody that inhibits cancer cells that overproduce the HER2 protein.Ajouté au bande de temps:
Date:
1 janv. 1998
Maintenaint
~ Il y a 26 ans
